IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific
IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL …

Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …

The inflammatory cytokines IL-1α and IL-1β orchestrate local and systemic inflammatory
responses underlying a broad spectrum of diseases. Three agents for reducing IL-1 …

Interleukin-I (IL-1) is the prototypic pro-inflammatory cytokine. There are two forms of IL-1, IL-
1α and IL-Iβ and in most studies, their biological activities are indistinguishable. IL-1 affects …

More than any other cytokine family, the IL-1 family of ligands and receptors is primarily
associated with acute and chronic inflammation. The cytosolic segment of each IL-1 receptor …

Abstract The interleukin (IL)-1 family member IL-1α is a ubiquitous and pivotal pro-
inflammatory cytokine. The IL-1α precursor is constitutively present in nearly all cell types in …

Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-
1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory …

Clinical and experimental evidence suggests that shock, arthritis, osteoporosis, colitis,
leukemia, diabetes, wasting and atherosclerosis are mediated, in part, by interleukin i (IL-1) …

Objective: To review publications relating to the blocking of interleukin 1 (IL1) as a strategy
for treating human disease, ranging from rheumatoid arthritis (RA) to Alzheimer's disease …

Approaches involving the blockade of inflammatory cytokines such as interleukin-1 and
tumor necrosis factor α (TNF-α) are entering mainstream clinical medicine: antibodies …